Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder

References

• American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. 4th edition, Text Revision (DSM-IV-TR). Washington DC: American Psychiatric Association.
   Google Scholar
• Barkley RA, McMurray MB, Edelbrock CS, Robbins K. 1990. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 86:184–192.
   PubMed Web of Science ®Google Scholar
• Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953.
   PubMed Web of Science ®Google Scholar
• Biederman J, Monuteaux MC, Kendrick E, Klein KL, Faraone SV. 2005. The CBCL as a screen for psychiatric comorbidity in paediatric patients with ADHD. Arch Dis Child 90:1010–1015.
   PubMed Web of Science ®Google Scholar
• Coghill D, Seth S. 2006. Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin Pharmacother 7:2119–2138.
   PubMed Web of Science ®Google Scholar
• Durá-Travé T, Yoldi-Petri ME, Gallinas-Victoriano F, Zardoya-Santos P. 2012. Effects of osmotic-release methylphenidate on height and weight in children with attention-deficit hyperactivity disorder (ADHD) following up to four years of treatment. J Child Neurol 27:604–609.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J, Morley CP, Spencer TJ. 2008. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 47:994–1009.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. 2004. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 24:24–29.
   PubMed Web of Science ®Google Scholar
• Frederich RC, Hamann A, Anderson S, Löllmann B, Lowell BB, Flier JS. 1995. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1:1311–1314.
   PubMed Web of Science ®Google Scholar
• Gökler B, Ünal F, Pehlivantürk B, Kültür EÇ, Akdemir D, Taner Y. 2004. Reliability and validity of schedule for affective disorders and schizophrenia for school age children-present and lifetime version-Turkish version (K-SADS-PL-T). [Article in Turkish] Turk J Child Adolesc Ment Health 11:109–116.
   Google Scholar
• Goldman RD. 2010. ADHD stimulants and their effect on height in children. Can Fam Physician 56:145–146.
   Google Scholar
• Gopal KV, Miller BR, Gross GW. 2007. Acute and sub-chronic functional neurotoxicity of methylphenidate on neural networks in vitro. J Neural Transm 114:1365–1375.
   Google Scholar
• Guy W. 1976. Clinical global impression. In: Guy W, editor. ECDEU assessment manual for psychopharmacology (DHEW Publication No. ADM 76–338). Rockville, MD: National Institute of Mental Health, pp 218–221.
   Google Scholar
• Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM. 1991. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350:230–232.
   PubMed Web of Science ®Google Scholar
• Işeri E, Kiliç BG, Senol S, Karabacak NI. 2007. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial. Methods Find Exp Clin Pharmacol 29:47–52.
   Google Scholar
• Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. 1997. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988.
   PubMed Web of Science ®Google Scholar
• Kernie SG, Liebl DJ, Parada LF. 2000. BDNF regulates eating behavior and locomotor activity in mice. EMBO J 19:1290–1300.
   PubMed Web of Science ®Google Scholar
• Klein RG, Mannuzza S. 1988. Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height. Arch Gen Psychiatry 45:1131–1134.
   PubMed Web of Science ®Google Scholar
• Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660.
   PubMed Web of Science ®Google Scholar
• Lebrun B, Bariohay B, Moyse E, Jean A. 2006. Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview. Auton Neurosci 30:126–127, 30–38.
   Google Scholar
• Lee SI, Hong SD, Kim SY, Kim EJ, Kim JH, Kim JH, et al. 2007. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 31:210–216.
   PubMed Web of Science ®Google Scholar
• Ludolph AG, Schaz U, Storch A, Liebau S, Fegert JM, Boeckers TM. 2006. Methylphenidate exerts no neurotoxic, but neuroprotective effects in vitro. J Neural Transm 113:1927–1934.
   PubMedGoogle Scholar
• Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M. 1996. Radioimmunoassay of leptin in human plasma. Clin Chem 42:942–946.
   PubMed Web of Science ®Google Scholar
• McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, Stein M. 2006. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 16:351–356.
   PubMed Web of Science ®Google Scholar
• Meredith GE, Callen S, Scheuer DA. 2002. Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res 949:218–227.
   PubMedGoogle Scholar
• Moungnoi P, Maipang P. 2011. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health. J Med Assoc Thai 94:S158–S163.
   Google Scholar
• MTA Cooperative Group. 2004. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 113:754–761.
   PubMed Web of Science ®Google Scholar
• No authors listed. 2011. Methylphenidate: growth retardation. Prescrire Int 20:238–239.
   Google Scholar
• Osei-Hyiaman D, Depetrillo M, Harvey-White J, Bannon AW, Cravatt BF, Kuhar MJ, et al. 2005. Cocaine- and amphetamine- related transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 81:273–282.
   PubMed Web of Science ®Google Scholar
• Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, et al. 2001. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105.
   PubMed Web of Science ®Google Scholar
• Pelleymounter MA, Cullen MJ, Wellman CL. 1995. Characteristics of BDNF-induced weight loss. Exp Neurol 131:229–238.
   PubMed Web of Science ®Google Scholar
• Pliszka S, AACAP Work Group on Quality Issues. 2007. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894–921.
   PubMed Web of Science ®Google Scholar
• Poulton A, Cowell CT. 2003. Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health 39:180–185.
   PubMed Web of Science ®Google Scholar
• Poulton A. 2005. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child 90:801–806.
   PubMed Web of Science ®Google Scholar
• Rapport MD, Moffitt C. 2002. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 22:1107–1131.
   PubMed Web of Science ®Google Scholar
• Rindi G, Necchi V, Savio A, Torsello A, Zoli M, Locatelli V, et al. 2002. Characterisation of gastric ghrelin cells in man and other mammals: studies in adult and fetal tissues. Histochem Cell Biol 117:511–519.
   PubMed Web of Science ®Google Scholar
• Rosenbaum M, Leibel RL, Hirsch J. 1997. Obesity. N Engl J Med 337:396–407.
   PubMed Web of Science ®Google Scholar
• Schachter HM, Pham B, King J, Langford S, Moher D. 2001. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165:1475–1488.
   PubMed Web of Science ®Google Scholar
• Smith BH, Waschbusch DA, Willoughby MT, Evans S. 2000. The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD). Clin Child Fam Psychol Rev 3:243–267.
   PubMedGoogle Scholar
• Smith FJ, Campfield LA, Moschera JA, Bailon PS, Burn P. 1996. Feeding inhibition by neuropeptide Y. Nature 382:307.
   PubMedGoogle Scholar
• Song DH, Choi S, Joung YS, Ha EH, Kim BN, Shin YJ, et al. 2012. Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study. Psychiatry Investig 9:257–262.
   Google Scholar
• Spencer T, Biederman J, Wilens T. 1998. Growth deficits in children with attention deficit hyperactivity disorder. Pediatrics 102:501–506.
   PubMed Web of Science ®Google Scholar
• Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C. 1992. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 59:99–106.
   PubMed Web of Science ®Google Scholar
• Spitzweg C, Heufelder AE. 1997. More clues from fat mice: leptin acts as an opponent of the hypothalamic neuropeptide Y system. Eur J Endocrinol 136:590–591.
   Google Scholar
• Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, et al. 2003. Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228.
   PubMed Web of Science ®Google Scholar
• Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. 2006. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 13:e50–e62.
   PubMedGoogle Scholar
• Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, et al. 2003. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 112:e404.
   PubMed Web of Science ®Google Scholar
• Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. 2003. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 60:204–211.
   PubMed Web of Science ®Google Scholar
• Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang CC, Itani SI, et al. 2002. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci 99:16309–16313.
   PubMed Web of Science ®Google Scholar
• Tsai SJ. 2007. Attention-deficit hyperactivity disorder may be associated with decreased central brain-derived neurotrophic factor activity: clinical and therapeutic implications. Med Hypotheses 68:896–899.
   PubMed Web of Science ®Google Scholar
• Wilding J, Widdowson P, Williams G. 1997. Neurobiology. Br Med Bull 53:286–306.
   Google Scholar
• Wynne K, Stanley S, McGowan B, Bloom S. 2005. Appetite control. J Endocrinol 184:291–318.
   PubMed Web of Science ®Google Scholar
• Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones KR, et al. 2003. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 6:736–742.
   PubMed Web of Science ®Google Scholar
• Yıldız Ö, Ağaoğlu B, Karakaya I, Şişmanlar ŞG, Çakın Memik N. 2010. Efficiency and tolerability of OROS-methylphenidate in Turkish children and adolescents with attention-deficit/hyperactivity disorder. Anatolian Journal of Psychiatry 11:44–50.
   Google Scholar
• Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, et al. 2012. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 7:e42676.
   PubMed Web of Science ®Google Scholar
• Yuan J, McCann U, Ricaurte G. 1997. Methylphenidate and brain dopamine neurotoxicity. Brain Res 767:172–175.
   PubMedGoogle Scholar
• Yurdakoş E, Mengi M. 2008. Hormonal and Neural Regulation of Feeding. Turkiye Klinikleri J Psychiatry-Special Topics [Article in Turkish] 1:8–12.
   Google Scholar
• Zhang H, Du M, Zhuang S. 2010. Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics 41:55–59.
   Google Scholar